Home / Treatments / Supartz
Supartz denials: what the review data shows
Independent reviewers have decided 19 published cases where an insurer denied Supartz — and they overturned the insurer 36.8% of the time. A denial for Supartz is a starting position, not a final answer.
Published decisions
19
2001–2026
Overturned
36.8%
7 denials reversed
Conditions behind supartz denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 8 | 50% |
| Osteoarthritis | 3 | 33.3% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 15 | 46.7% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 0% |
Typical time to a decision
21 days
Most land between 14 and 24 days
Handled as urgent
10.5%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Supartz injections weekly for four doses. Evidence from systematic reviews and randomized controlled trials indicate that although viscosupplementation may relieve knee pain in some patients with osteoarthritis, data has not established which patients will benefit. Guidelines from the American Academy of Orthopedic Surgeons (AAOS) indicate that the data on the safety and efficacy of viscosupplementation remain inconclusive. As such, the AAOS does not currently recommend viscosupplementation as routine treatment for osteoarthritis of the knees. Viscosupplementation is reserved for patients with a history of lasting benefit from prior injections and in cases where the remaining options are limited.
Nature of Statutory Criteria/Case Summary: An enrollee has reimbursement for Supartz injections provided by Torrance Memorial Physicians and prospective authorization and coverage for future treatment with hyaluronan injection(s) (series of Supartz injections or Monovisc injection) in the left knee.An exhaustive review of the current medical literature pertaining to viscosupplementation reveals mixed results. Evidence from eight systematic reviews and six randomized controlled trials indicates that although viscosupplementation may relieve knee pain in some individuals with osteoarthritis, it is not known as to which individuals will benefit. Different studies have tried mixing hyaluronic acid with corticosteroids, platelet rich plasma, and other agents to make it more effective.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for Supartz, for history of arthritic left knee pain. A magnetic resonance of the left lower extremity joint without contrast was suggestive of degenerative osteoarthritis, radial tear at the junction of posterior horn with posterior root of the medial meniscus, sprain pattern without tear, and moderate to large joint effusion with a leaking popliteal cyst. She received a Depo-Medrol injection in the left knee and reported minimal relief. Her orthopedist prescribed Supartz. A magnetic resonance imaging report of the left knee revealed high grade loss of articular cartilage with subarticular fibro-osseous changes and stress marrow edema medial and patellofemoral compartments. These findings suggest degenerative osteoarthritis.
Nature of Statutory Criteria/Case Summary: An enrollee has requested Supartz injections for treatment of his osteoarthritis. The physician reviewer found that carefully conducted double-blinded studies published in the medical literature do not demonstrate any clinical effect from hyaluronan injections. In addition, there is a recognized incidence of aseptic inflammatory reactions due to allergic response and risk of iatrogenic infection within the joint. A recent meta-analysis of the efficacy of viscosupplementation concluded after review of a total of 89 trials involving 12,667 patients with knee osteoarthritis that viscosupplementation is associated with a small and clinically irrelevant benefit and that there is an increased risk of serious adverse effects.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Supartzwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.